Arbutus Biopharma (ABUS) Deferred Taxes (2015 - 2019)

Arbutus Biopharma has disclosed Deferred Taxes across 5 years of filings, most recently posting -$12.7 million for Q3 2019.

• Deferred Taxes for Q3 2019 came in at -$12.7 million, down 195.68% year-over-year; the trailing twelve-month figure through Dec 2020 was -$12.7 million (up 25.27% YoY), and the FY2019 annual result was -$12.7 million, down 195.68% from the prior year.
• Deferred Taxes came in at -$12.7 million for Q3 2019 at Arbutus Biopharma, down from -$4.3 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of -$989000.0 in Q4 2015 to a low of -$64.9 million in Q2 2016.
• The 5-year median for Deferred Taxes is -$15.2 million (2015), against an average of -$23.2 million.
• Across the five-year window, Deferred Taxes sank 3964.41% in 2016 and jumped 39.5% in 2017, its largest moves.
• Arbutus Biopharma's Deferred Taxes stood at -$989000.0 in 2015, then tumbled by 3964.41% to -$40.2 million in 2016, then surged by 39.5% to -$24.3 million in 2017, then surged by 82.39% to -$4.3 million in 2018, then sank by 195.68% to -$12.7 million in 2019.
• The last three Deferred Taxes figures came in at -$12.7 million (Q3 2019), -$4.3 million (Q3 2018), and -$24.3 million (Q4 2017), per Business Quant data.